StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
| April 09, 2025 | Timely Disclosure Information | StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease) |
|---|---|---|
| April 03, 2025 | Timely Disclosure Information | StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans |
| April 02, 2025 | Timely Disclosure Information | StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke |
| March 17, 2025 | Financial Results Presentation Materials | Presentation Materials for Six Months Ended January 31, 2025 |
| March 12, 2025 | Financial Results | Non-consolidated Financial Results for the Six Months Ended January 31, 2025 [Japanese GAAP] |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
